Dinesh Patel, Protagonist Therapeutics CEO

De­spite mid-stage plaque pso­ri­a­sis win, J&J ap­pears un­de­cid­ed on PhI­II for part­ner's IL-23 drug

J&J and biotech part­ner Pro­tag­o­nist Ther­a­peu­tics claimed a Phase IIb win in plaque pso­ri­a­sis Tues­day morn­ing. But near-term plans for the drug re­main murky.

The study, look­ing at an oral IL-23 drug called JNJ-2113, hit its pri­ma­ry end­point in adults with mod­er­ate-to-se­vere plaque pso­ri­a­sis, the com­pa­nies said. Re­searchers saw more pa­tients who took the drug achieve PASI-75, or at least 75% im­prove­ment in skin le­sions, by a sta­tis­ti­cal­ly sig­nif­i­cant mar­gin com­pared to place­bo in all five treat­ment co­horts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.